Abstract 2866
Background
In the Netherlands, hospice care is provided in professional-driven hospices and volunteer-driven hospices. To date, insight is lacking whether the care provided in hospices is appropriate to meet the patient’s needs and wishes. The aim is to gain insight into the characteristics of patients admitted in hospices, their needs and wishes and the care they receive.
Methods
A retrospective patient record study of 1200 hospice patients in the Netherlands. Preliminary results are shown for the first 203 patients. Inclusion criteria are deceased, adult patients admitted in hospice in 2017-2018.The following outcomes were included: Patient characteristics: demographics, disease characteristics, multidimensional symptoms, needs and wishes. Care characteristics: measurement instruments and multidimensional care. Descriptive statistisc was used for analyses.
Results
Preliminary results of 203 patients (mean age 74.8 years, 51.8% woman, 84% cancer diagnoses) from 13 hospices show that initiative for admission is mostly taken by the patient or their family (65.7%). Reasons for admission were described as physical symptoms (73.1%), preferred location of dying (16.1%) and social problems (9.7%). Patients were mostly admitted for last-resort (96.4%) and most patients were in the phase of symptom palliation (79.4%). Problems that were most described were delirium (18.6%), decubitus (12.4%) and edema (6.2%). On average, 10.6 interventions were performed in the first 72 hours per patient. Most were within the physical dimension (76.6%) and least in the social dimension (2.3%). Of the 11 different measurement tools identified, a symptom diary (20.7%) and a palliative assessment (17.2%) were most frequent used.
Conclusions
A preliminary overview of hospice patients and the care they receive was presented. The study is work in progress. Additional data and a comparison between organizational structures of hospices will be presented during the congress.
Clinical trial identification
Editorial acknowledgement
R. Koorn, F. van der Baan, E. de Graaf, S. Teunissen.
Legal entity responsible for the study
S.C.C.M. Teunissen.
Funding
ZonMw.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract